［1］Rathmann W，Giani G. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030［J］.Diabetes Care, 2004,27(10)：2568-2569.
［2］Whiting DR, Guariguata L, Weil C, et al. IDF diabetes atlas: global estimates of the prevalence of diabetes for 2011 and 2030［J］.Diabetes Research & Clinical Practice, 2011, 94(3):311-321.
［3］Yang W，Lu J, Weng J,et al. Prevalence of diabetes among men and women in China［J］.N Engl J Med, 2010，362(12)：1090-1101.
［4］Matthews DR,Cull CA,Stratton IM,et al. UKPDS 26: Sulphonylurea failure innon-insulin-dependent diabetic patients over six years［J］.UK Prospective DiabetesStudy (UKPDS) Group Diabet Med, 1998，15(4)：297-303.
［5］Listed N.UKPDS 28: a randomized trial of efficacy of early addition of metformin in sulfonylurea-treated type 2 diabetes. UK Prospective Diabetes Study Group［J］.Diabetes Care，1998，21(1)：87-92.
［6］Cornu M，Modi H，Dan K, et al. Glucagon-like peptide-1 increases β-cell glucose competence and proliferation by translational induction of insulin-like growth factor-1 receptor expression［J］.J Biol Chem, 2010，285(14)：10538.
［7］Akarte AS，Srinivasan BP，Gandhi S. Vildagliptin selectively ameliorates GLP-1, GLUT4, SREBP-1c mRNA levels and stimulates β-cell proliferation resulting in improved glucose homeostasis in rats with streptozotocin-induced diabetes［J］.J Diabetes Complications, 2012，26(4)：266-274.
［8］陈岩，陈淼．2型糖尿病采用格列美脲治疗的有效性和药理探析［J］．中国现代药物应用，2014，8(23):66
［9］Nauck MA, Niedereichholz U, Ettler R, et al. Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans.［J］.American Journal of Physiology, 1997, 273(5):981.
［10］Nauck MA, Heimesaat MM, Orskov C, et al. Preserved incretin activity of glucagon-like peptide 1 ［7-36 amide］ but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus［J］.Journal of Clinical Investigation, 1993, 91(1):301-307.
［11］Flint A, Raben A, Astrup A, et al. Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans［J］.Journal of Clinical Investigation, 1998, 101(3):515-520.
［12］胡艺琼，陈晓文．沙格列汀与阿卡波糖治疗血糖控制不佳伴超重2型糖尿病患者的临床疗效比较［J］．临床合理用药杂志，2016，9(11):13-15. |
